A comprehensive study of polymorphisms in ABCB1, ABCC2 and ABCG2 and lung cancer chemotherapy response and prognosis

International Journal of Cancer

Volumn 131, Issue 12, 2012, Pages 2920-2928

  Campa, Daniele ^a,b   Müller, Phillip ^a   Edler, Lutz ^a   Knoefel, Lena ^a   Barale, Roberto ^b   Heussel, Claus P ^a,c,d   Thomas, Michael ^c,d   Canzian, Federico ^a   Risch, Angela ^a,d  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF PISA   (Italy)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d German Center for Lung Research   (Germany)

Author keywords

ABCB1; ABCC2; ABCG2; lung cancer; pharmacogenetics; survival

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; ETOPOSIDE; GEMCITABINE; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; PLATINUM COMPLEX;

ABCB1 GENE; ABCC2 GENE; ABCG2 GENE; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PROGNOSIS; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DNA DETERMINATION; DRUG RESPONSE; FEMALE; GENE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHARMACOGENETICS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; FEMALE; HAPLOTYPES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; P-GLYCOPROTEIN; POLYMORPHISM, GENETIC; PROGNOSIS;

EID: 84867878662     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27567     Document Type: Article

References (46)

1. Janssen-Heijnen ML, Coebergh JW,. The changing epidemiology of lung cancer in Europe. Lung Cancer 2003; 41: 245-58.
2. Efferth T, Volm M,. Pharmacogenetics for individualized cancer chemotherapy. Pharmacol Ther 2005; 107: 155-76.
3. Han JY, Lim HS, Shin ES, et al. Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin. J Clin Oncol 2006; 24: 2237-44.
4. Sohn JW, Lee SY, Lee SJ, et al. MDR1 polymorphisms predict the response to etoposide-cisplatin combination chemotherapy in small cell lung cancer. Jpn J Clin Oncol 2006; 36: 137-41.
5. Muller PJ, Dally H, Klappenecker CN, et al. Polymorphisms in ABCG2, ABCC3 and CNT1 genes and their possible impact on chemotherapy outcome of lung cancer patients. Int J Cancer 2009; 124: 1669-74.
6. Kiyotani K, Mushiroda T, Imamura CK, et al. Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients. J Clin Oncol 2010; 28: 1287-93.
7. Kim WJ, Lee JH, Yi J, et al. A nonsynonymous variation in MRP2/ABCC2 is associated with neurological adverse drug reactions of carbamazepine in patients with epilepsy. Pharm Genom 2010; 20: 249-56.
8. Yoh K, Ishii G, Yokose T, et al. Breast cancer resistance protein impacts clinical outcome in platinum-based chemotherapy for advanced non-small cell lung cancer. Clin Cancer Res 2004; 10: 1691-7.
9. Cascorbi I, Haenisch S,. Pharmacogenetics of ATP-binding cassette transporters and clinical implications. Methods Mol Biol 2010; 596: 95-121.
10. Han JY, Lim HS, Yoo YK, et al. Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer. Cancer 2007; 110: 138-47.
11. Suzuki H, Sugiyama Y,. Single nucleotide polymorphisms in multidrug resistance associated protein 2 (MRP2/ABCC2): its impact on drug disposition. Adv Drug Deliv Rev 2002; 54: 1311-31.
12. Szakacs G, Paterson JK, Ludwig JA, et al. Targeting multidrug resistance in cancer. Nat Rev 2006; 5: 219-34.
13. Scheffer GL, Pijnenborg AC, Smit EF, et al. Multidrug resistance related molecules in human and murine lung. J Clin Pathol 2002; 55: 332-9.
14. Fardel O, Lecureur V, Guillouzo A, et al. The P-glycoprotein multidrug transporter. Gen Pharmacol 1996; 27: 1283-91.
15. Cui Y, Konig J, Buchholz JK, et al. Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells. Mol Pharmacol 1999; 55: 929-37.
16. Liu L, Fan L, Peng X, et al. MDR1 C2005T polymorphism changes substrate specificity. Cancer Chemother Pharmacol 2010; 66: 617-23.
17. Krishnamurthy P, Schuetz JD,. Role of ABCG2/BCRP in biology and medicine. Annu Rev Pharmacol Toxicol 2006; 46: 381-410.
18. Imai Y, Nakane M, Kage K, et al. C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance. Mol Cancer Ther 2002; 1: 611-6.
19. Yanase K, Tsukahara S, Mitsuhashi J, et al. Functional SNPs of the breast cancer resistance protein-therapeutic effects and inhibitor development. Cancer Lett 2006; 234: 73-80.
20. Mizuarai S, Aozasa N, Kotani H, et al. Single nucleotide polymorphisms result in impaired membrane localization and reduced atpase activity in multidrug transporter ABCG2. Int J Cancer 2004; 109: 238-46.
21. Sandusky GE, Mintze KS, Pratt SE, et al. Expression of multidrug resistance-associated protein 2 (MRP2) in normal human tissues and carcinomas using tissue microarrays. Histopathology 2002; 41: 65-74.
22. Kool M, de Haas M, Scheffer GL, et al. Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologs of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res 1997; 57: 3537-47.
23. Minemura M, Tanimura H, Tabor E, et al. Overexpression of multidrug resistance genes MDR1 and cMOAT in human hepatocellular carcinoma and hepatoblastoma cell lines. Int J Oncol 1999; 15: 559-63.
24. Taniguchi K, Wada M, Kohno K, et al. A human canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplatin-resistant human cancer cell lines with decreased drug accumulation. Cancer Res 1996; 56: 4124-9.
25. Sissung TM, Baum CE, Kirkland CT, et al. Pharmacogenetics of membrane transporters: an update on current approaches. Mol Biotechnol 2010; 44: 152-67.
26. Kiyotani K, Mushiroda T, Kubo M, et al. Association of genetic polymorphisms in SLCO1B3 and ABCC2 with docetaxel-induced leukopenia. Cancer Sci 2008; 99: 967-72.
27. Sun Z, Chen J, Aakre J, et al. Genetic variation in glutathione metabolism and DNA repair genes predicts survival of small-cell lung cancer patients. Ann Oncol 2010; 21: 2011-6.
28. Haenisch S, May K, Wegner D, et al. Influence of genetic polymorphisms on intestinal expression and rifampicin-type induction of ABCC2 and on bioavailability of talinolol. Pharmacogen Genom 2008; 18: 357-65.
29. Haenisch S, Zimmermann U, Dazert E, et al. Influence of polymorphisms of ABCB1 and ABCC2 on mRNA and protein expression in normal and cancerous kidney cortex. Pharm J 2007; 7: 56-65.
30. Laechelt S, Turrini E, Ruehmkorf A, et al. Impact of ABCC2 haplotypes on transcriptional and posttranscriptional gene regulation and function. Pharm J 2011.
31. International Union Against Cancer (UICC) TNM Classification of Malignant Tumours 7th edn., Eds:, Sobin LH, Gospodarowicz MK, Wittekind C,. Wiley-Blackwell, 2009.
32. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-16.
33. Barrett JC, Fry B, Maller J, et al. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21: 263-5.
34. de Bakker PI, Yelensky R, Pe'er I, et al. Efficiency and power in genetic association studies. Nat Gen 2005; 37: 1217-23.
35. Chen B, Wilkening S, Drechsel M, et al. SNP-tools: a compact tool package for analysis and conversion of genotype data for MS-Excel. BMC Res Notes 2009; 2: 214.
36. Gabriel SB, Schaffner SF, Nguyen H, et al. The structure of haplotype blocks in the human genome. Science 2002; 296: 2225-9.
37. Gao X, Starmer J, Martin ER, et al. A multiple testing correction method for genetic association studies using correlated single nucleotide polymorphisms. Gen Epidemiol 2008; 32: 361-9.
38. Li J, Ji L,. Adjusting multiple testing in multilocus analyses using the eigenvalues of a correlation matrix. Heredity 2005; 95: 221-7.
39. Onuki N, Wistuba II, Travis WD, et al. Genetic changes in the spectrum of neuroendocrine lung tumors. Cancer 1999; 85: 600-7.
40. Rodenhuis S, Slebos RJ,. Clinical significance of ras oncogene activation in human lung cancer. Cancer Res 1992; 52: 2665s-9s.
41. Hida T, Yatabe Y, Achiwa H, et al. Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res 1998; 58: 3761-4.
42. Eymin B, Gazzeri S, Brambilla C, et al. Distinct pattern of E2F1 expression in human lung tumors: E2F1 is upregulated in small cell lung carcinoma. Oncogene 2001; 20: 1678-87.
43. Eymin B, Leduc C, Coll JL, et al. p14ARF induces G2 arrest and apoptosis independently of p53 leading to regression of tumors established in nude mice. Oncogene 2003; 22: 1822-35.
44. Kaye FJ,. RB and cyclin dependent kinase pathways: defining a distinction between RB and p16 loss in lung cancer. Oncogene 2002; 21: 6908-14.
45. Osada H, Tatematsu Y, Yatabe Y, et al. Frequent and histological type-specific inactivation of 14-3-3sigma in human lung cancers. Oncogene 2002; 21: 2418-24.
46. Lagas JS, Fan L, Wagenaar E, et al. P-glycoprotein (P-gp/Abcb1), Abcc2, and Abcc3 determine the pharmacokinetics of etoposide. Clin Cancer Res 2010; 16: 130-40.